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The threatened trade in human ova 
It is well known that there is a shortage of human ova for in vitro fertilization (IVF) purposes, but little attention has 
been paid to the way in which the demand for ova in stem-cell technologies is likely to exacerbate that shortfall and 
create a trade in human eggs. Because the 'Dolly' technology relies on enucleated ova in large quantities, allowing 
for considerable wastage, there is a serious threat that commercial and research demands for human eggs will grow 
exponentially from the combination of these two pressures. In the absence of legal regulation in the United Kingdom, 
and in the context of a globalized trade in human organs, we face a 'Wild West' situation in genetic and 
biotechnological research that involves human ova.  
  
A recent example shows how ineffective the Human Fertilisation and Embryology 
Act 1990 is likely to be in regulating or stopping this trade. In a research trial, 
Leeds General Hospital has admitted to paying women £1,500 to undergo an IVF 
cycle to harvest their eggs. Commentators in the UK might have thought we 
would be protected from the excesses that are prevalent in the United States, 
where there are documented cases of extraction for profit of up to 70 ova from a 
single cycle in one woman (who nearly died in the process)1. It turns out, 
however, that if eggs are never fertilized, the Human Fertilisation and E
Authority is powerless to intervene. In the Leeds case, the eggs were used by a 
pharmaceutical company for trials of improved techniques for in vitro maturation
during which eggs are ripened in the laboratory instead of in the ovaries. They
were never fertilized. This would also be true of eggs used in stem-cell 
technologies. 
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So we face a future situation in which women in the United Kingdom are offered whatever the Local Research Ethics 
Committee (LREC) will condone and the 'market' will bear. That market is also likely to become globalized: already 
there are indications that eastern European women's ova are being extracted and sold illicitly by health-care 
professionals — a recent Croatian case involving two gynaecologists being a recent example. Elsewhere in eastern 
Europe — particularly in Russia, Bulgaria, Romania, Georgia and the Ukraine — a well-organized network that trades 
more generally in human organs has already been documented2. 
In the Leeds case, the LREC rejected an original offer by the drug company of £4,000 per woman, on the grounds 
that this would constitute a financial inducement rather than recompense for subjects' "time and hardship". By the 
drug company's standards, the United Kingdom would represent a cheap market even at that price, as the going rate 
in the United States is US $30,000–$40,000 for one cycle's eggs. The eggs of women from eastern Europe or 
developing countries would presumably be even cheaper3. Unless legislation action is taken quickly to close the 
loophole in the Human Fertilisation and Embryology Act — that leaves unregulated the trade in eggs that are not 
intended to be fertilized — we face the risk of a 'free-for-all' that will imperil both women's health and the future of 
stem-cell research. 
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